May/June 1999

Vol 6, No 3 CME Pretest

In this issue, the topic of breast cancer is addressed. First, answer the pretest questions below. After reading the articles, proceed with answering the CME posttest questions.

This Journal provides 4 hours of Category 1 Continuing Medical Education

Complimentary CME Credits

Physicians can earn 4 credit hours of Category 1 for the Physician's Recognition Award of the American Medical Association by reading the material in this issue and successfully answering the questions in the posttest at the end of this issue. Complete instructions are given on the posttest pages. Successfully answering 30 or more questions will earn 4 credit hours. CME is presented by an unrestricted educational grant from Bristol-Myers Oncology Division.

Educational Objectives

After reading this issue of Cancer Control, clinicians will be expected to:

• utilize recent advances in breast cancer biology and management to improve patient care,
• recognize associations between bone radiography and pathology of malignant lesions, and
• be aware of the association between infections and cancer biology.

Release Date: May 1, 1999
Expiration Date: May 1, 2000

Pretest

1. Which is the best HER-2 test to evaluate the chance for a patient with metastatic breast cancer will benefit from trastuzumab?

a. enzyme-linked immunosorbent assay (ELISA)

b.fluorescence in situ hybridization (FISH) kit

c. HercepTest

d.undefined

2. In trials of pamidronate for osteolytic breast cancer reported by Hortobagyi et al, the median time to first fracture in the placebo group was 12.8 months. What was the median time for the pamidronate-treated group?

a. 8.4 months

b. 14.6 months

c. 25.2 months

d. 34.3 months

3.What is the death rate from the endometrial cancers that developed in the NSABP-led cancer-prevention study of tamoxifen?

a. 0%

b. 5%

c. 10%

d. 15%